A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced CancerRobert H. Jones, Udai Banerji, Alan Anthoney et al.|Clinical Cancer Research|2022Cited by 41
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with EribulinGwo‐Yaw Ho, Holly E. Barker, Elizabeth L. Kyran et al.|Cancer Research|2022Cited by 26
A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.Udai Banerji, Robert H. Jones, Elizabeth Ruth Plummer et al.|Journal of Clinical Oncology|2019Cited by 20
CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer—A Multicenter AnalysisChristoph Wohlmuth, Taymaa May, Vladimir Djedovic et al.|Cancers|2022Cited by 13
Mean plasma SRA737 concentration over time from A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced CancerRobert H. Jones, Udai Banerji, Ruth Plummer et al.|Unknown|2023Cited by 2